SWX:AMS - AMS Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileHeadlinesChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email American Shared Hospital Services leases radiosurgery and radiation therapy equipment to health care providers in the United States. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia. It also provides image guided radiation therapy systems that integrate imaging and detection components into an accelerator, which allows clinicians to plan treatment, verify positioning, and deliver treatment. In addition, the company offers financing services for Leksell Gamma Knife units. Further, it provides proton beam therapy equipment and services in Orlando, Florida and Long Beach, California, as well as offers planning, installation, reimbursement, and marketing support services to its customers. As of March 1, 2018, it operated 16 Gamma Knife units, as well as served 17 medical centers in 15 states of the United States. American Shared Hospital Services was founded in 1980 and is based in San Francisco, California. Receive AMS News and Ratings via Email Sign-up to receive the latest news and ratings for AMS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange SWX Industry Specialized Health Services Sub-IndustryN/A SectorMedical SymbolSWX:AMS CUSIPN/A Webwww.ashs.com PhoneN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap$0.00 AMS (SWX:AMS) Frequently Asked Questions What is AMS's stock symbol? AMS trades on the SWX under the ticker symbol "AMS." What is the consensus analysts' recommendation for AMS? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMS in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of AMS's key competitors? Some companies that are related to AMS include "WideCells Group PLC" (WDC), Advanced Accelerator Application (AAAP), Altimmune (ALT), Apollo Medical (AMEH), Bayer (BAYN), BioMerieux (BMXMF), Bohai Pharmaceuticals (BOPH), Brain Resource (BRRZY), Can-Fite Biopharma (CANF), Cannabix Technologies (BLOZF), Carl Data Solutions (CRL), Check Cap (CHEK), Circassia Pharmaceuticals (CIR), Cosmos (COSM) and Cronos Group (CRON). Who are AMS's key executives? AMS's management team includes the folowing people: Dr. Ernest A. Bates, Founder, Chairman & CEO (Age 81)Mr. Craig K. Tagawa, Sr. VP, Chief Operating & Financial Officer (Age 64)Mr. Ernest R. Bates, VP of Sales & Bus. Devel. (Age 51)Mr. Willie R. Barnes, Corp. Sec. (Age 86) Has AMS been receiving favorable news coverage? News headlines about AMS stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AMS earned a news sentiment score of 0.11 on Accern's scale. They also assigned media headlines about the company an impact score of 45.11 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. MarketBeat Community Rating for AMS (SWX AMS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 6 (Vote Outperform)Underperform Votes: 6 (Vote Underperform)Total Votes: 12MarketBeat's community ratings are surveys of what our community members think about AMS and other stocks. Vote "Outperform" if you believe AMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/21/2018 by MarketBeat.com StaffFeatured Article: Should I invest in "strong buy" stocks?